Research Topics
| J P CostantinoSummaryAffiliation: University of Pittsburgh Country: USA Publications
| Collaborators
|
Detail Information
Publications
Benefit/risk assessment of SERM therapy: clinical trial versus clinical practice settingsJ P Costantino
Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pennsylvania 15213, USA
Ann N Y Acad Sci 949:280-5. 2001..This paper summarizes the uses of B/rA in the clinical practice and clinical trial settings and describes the constraints of the methodology as it is being applied to the assessment of therapy with SERMs...- Reminiscence of Samuel H. Wieand: the NSABP YearsJoseph P Costantino
NSABP Biostatistical Center, 201 N. Craig Street, Suite 350, Pittsburgh, PA 15213, USA
Lifetime Data Anal 14:16-7. 2008 - Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: an alternative viewJ P Costantino
University of Pittsburgh, Graduate School of Public Health, 130 DeSoto Street, Room 316 Parran Hall, Pittsburgh, PA 15261, USA
Clin Breast Cancer 2:41-6. 2001..The drug cannot be used indiscriminately due to the potential side effects, but benefit/risk assessment methodology can be used to identify substantial numbers of women in whom treatment would provide a net beneficial effect... - The impact of hormonal treatments on quality of life of patients with metastatic breast cancerJoseph Costantino
National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, and Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pennsylvania 15261, USA
Clin Ther 24:C26-42. 2002..Hormonal therapy (HT) is often used to treat hormone receptor-positive MBC, with the primary treatment goal of reducing both disease burden and patient suffering... - Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyB Fisher
National Surgical Adjuvant Breast and Bowel Project, Allegheny University of the Health Sciences, Pittsburgh, PA 15212 5234, USA
J Natl Cancer Inst 90:1371-88. 1998..To test this hypothesis, the National Surgical Adjuvant Breast and Bowel Project initiated the Breast Cancer Prevention Trial (P-1) in 1992... - Pathobiology of small invasive breast cancers without metastases (T1a/b, N0, M0): National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-21Edwin R Fisher
National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, Pennsylvania, USA
Cancer 110:1929-36. 2007..Uncertainties continue to exist concerning the outcomes and management of small (T1a/b N0 M0) invasive breast cancers... 
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trialDavid N Krag
National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, PA, USA
Lancet Oncol 11:927-33. 2010....- Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trialsNeal W Wilkinson
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
Ann Surg Oncol 17:959-66. 2010.... - Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancerSoonmyung Paik
Division of Pathology, Operations Center, and Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
J Clin Oncol 24:3726-34. 2006..The relationship between the RS and chemotherapy benefit is not known... - Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findingB Fisher
National Surgical Adjuvant Breast and Bowel Project Scientific Director s Office, Pittsburgh, PA 15261, USA
J Clin Oncol 14:1982-92. 1996.... - Long-term tamoxifen citrate use and potential ocular toxicityM B Gorin
Department of Ophthalmology, School of Medicine, University of Pittsburgh, Pennsylvania 15213, USA
Am J Ophthalmol 125:493-501. 1998..To estimate the prevalence of abnormalities in visual function and ocular structures associated with the long-term use of tamoxifen citrate... - Is sentinel node biopsy necessary in conservatively treated DCIS?Thomas B Julian
National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, Pennsylvania, USA
Ann Surg Oncol 14:2202-8. 2007..Its use in patients with DCIS versus local excision (LE), observation, and/or breast irradiation remains in question... - Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancerVictor G Vogel
NSABP, Pittsburgh, PA 15212, USA
Cancer Prev Res (Phila) 3:696-706. 2010..These results have important public health implications and clarify that both raloxifene and tamoxifen are good preventive choices for postmenopausal women with elevated risk for breast cancer... - National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situVictor G Vogel
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 3180, USA
Clin Cancer Res 9:495S-501S. 2003..Outcomes will include both ipsilateral and contralateral new breast cancer and recurrences, as well as the occurrence of regional and distant disease. Enrollment will begin in early 2003... - Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial InvestigatorsS E Reis
Cardiovascular Institute, University of Pittsburgh Medical Center, PA 15213, USA
J Natl Cancer Inst 93:16-21. 2001..The National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial (BCPT) is the only clinical trial that provides data to assess the cardiovascular effects of tamoxifen in women with and without CHD... - The landmark surgical trials of the National Surgical Adjuvant Breast and Bowel ProjectD Lawrence Wickerham
National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, Pennsylvania 15212, USA
World J Surg 30:1138-46. 2006.... 
Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trialSandra M Swain
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
Breast Cancer Res Treat 113:315-20. 2009..These results can be used to inform premenopausal women about the risk and time course of amenorrhea associated with this common adjuvant therapy regimen, along with the effects on symptoms and QOL...- The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trialVictor G Vogel
The National Surgical Adjuvant Breast and Bowel Project, NSABP Foundation Inc, Pittsburgh, PA, USA
Clin Breast Cancer 3:153-9. 2002..0% of black women, and 44.5% of Hispanic women. The trial will recruit a total of 22,000 postmenopausal women and is powered to demonstrate superior efficacy of either agent or their equivalence in reducing the incidence of primary breast.. - Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trialVictor G Vogel
Magee Womens Hospital, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 3221, USA
JAMA 295:2727-41. 2006..Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis... - Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowelAlphonse G Taghian
National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Graduate School of Public Health, University of Pittsburgh, PA, USA
J Clin Oncol 24:3927-32. 2006..In this study, we assess patterns of locoregional failure (LRF) in LN-negative patients who underwent mastectomy, either with or without adjuvant chemotherapy or hormonal therapy and without postmastectomy radiation therapy (PMRT)... - Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trialStephanie R Land
National Surgical Adjuvant Breast and Bowel Project NSABP Operations and Biostatistical Centers, Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
JAMA 295:2742-51. 2006..Tamoxifen has been approved for breast cancer risk reduction in high-risk women, but how raloxifene compares with tamoxifen is unknown... - Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07Stephanie R Land
National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA 15213, USA
J Clin Oncol 25:2205-11. 2007..Definitive analysis revealed an increase in 4-year disease-free survival from 67.0% to 73.2% in favor of FLOX. This study compares neurotoxicity between the treatments... - Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32Stephanie R Land
National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistics Center, University of Pittsburgh, Pittsburgh, PA 15213, USA
J Clin Oncol 28:3929-36. 2010..We report the definitive patient-reported outcomes (PRO) comparisons... - Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approachesStephanie R Land
National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA 15213, USA
J Clin Oncol 25:5113-20. 2007..We describe the effectiveness of several interventions and of observational factors... - Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancerStewart J Anderson
Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15261, USA
J Clin Oncol 27:2466-73. 2009..Locoregional failure (LRF) after breast-conserving therapy (BCT) is associated with increased risk of distant disease and death. The magnitude of this risk has not been adequately characterized in patients with lymph node-negative disease... - Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20Eleftherios P Mamounas
National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Departmentof Biostatistics, Graduate School of Public Health, University of Pittsburgh, USA
J Clin Oncol 28:1677-83. 2010.... - Breast cancer risk factors and mammographic breast density in women over age 70Francesmary Modugno
Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA
Breast Cancer Res Treat 97:157-66. 2006..Breast density is a strong risk factor for breast cancer, but little is known about factors associated with breast density in women over 70... - Lower-category benign breast disease and the risk of invasive breast cancerJiping Wang
Biostatistical Center, National Surgical Breast and Bowel Project and Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA
J Natl Cancer Inst 96:616-20. 2004..This report evaluates the risk of breast cancer associated with this lower-category BBD (LC-BBD)... - Nonparametric inference on median residual life functionJong Hyeon Jeong
Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA 15261, USA
Biometrics 64:157-63. 2008.... - Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized StudyR Day
National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Pittsburgh, PA, USA
J Natl Cancer Inst 93:1615-23. 2001.... - Validation studies for models projecting the risk of invasive and total breast cancer incidenceJ P Costantino
National Surgical Adjuvant Breast and Bowel Project, Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, PA, USA
J Natl Cancer Inst 91:1541-8. 1999..We assessed the validity of both models by employing data from women enrolled in the Breast Cancer Prevention Trial... - S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancerJ Bryant
NSABP, University of Pittsburgh, PA 15213, USA
Breast Cancer Res Treat 51:239-53. 1998..The diversity of risk in the B-14 population was more extreme than is generally recognized. The prognostic capabilities of S-phase, tumor size, and PgR status were sharply attenuated as the time from surgery increased... - The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel ProjectD Lawrence Wickerham
NSABP Operations Office, Biostatistical Center and Graduate School of Public Health, University of Pittsburgh, and Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA
Semin Oncol 35:522-9. 2008.... - Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trialNeil Abramson
National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA, USA
J Natl Cancer Inst 98:904-10. 2006..However, the involvement of hypercoagulability factors in this association is unclear... - Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 studyBernard Fisher
Operations Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
J Natl Cancer Inst 97:1652-62. 2005..Side effects of varying clinical significance were observed. The trial was unblinded because of the positive results, and follow-up continued. This report updates our initial findings... - A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37Irene L Wapnir
National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA, USA
Clin Breast Cancer 8:287-92. 2008..Although multidrug regimens are preferred, the agents, doses, and use of supportive therapy are at the discretion of the investigator... - The use of tamoxifen and raloxifene for the prevention of breast cancerD Lawrence Wickerham
Operations Center, National Surgical Adjuvant Breast and Bowel Project, Allegheny Center, Pittsburgh, PA 15212, USA
Recent Results Cancer Res 181:113-9. 2009..51 vs 2.11 per 1,000; RR, 1.40; 95% CI, 0.98-2.00). There were 36 cases of uterine cancer with tamoxifen and 23 cases with raloxifene (RR, 0.63; 95% CI, 0.35-1.08)... - Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancerYu Shen
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
J Natl Cancer Inst 100:1448-53. 2008..Its effect on the time to first diagnosis of breast cancer has not been reported. We used information from the randomized, placebo-controlled Breast Cancer Prevention Trial (BCPT) to make that evaluation... - Pathologic variables predictive of breast events in patients with ductal carcinoma in situEdwin R Fisher
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
Am J Clin Pathol 128:86-91. 2007..The similar predictive role of comedo necrosis in this study and that reported previously from NSABP B-17 (total of 2,079 patients) strongly supports its role as a simple high-risk predictor for ipsilateral breast tumor recurrences... - Is tamoxifen a risk factor for retinal vaso-occlusive disease?Michael B Gorin
Department of Ophthalmology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
Retina 25:523-6. 2005 - Multivariate predictors of failed prehospital endotracheal intubationHenry E Wang
Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Acad Emerg Med 10:717-24. 2003..This study sought to use multivariate logistic regression to identify a set of factors associated with failed adult out-of-hospital ETI... - Issues and findings in the evaluation of occupational risk among women high nickel alloys workersV C Arena
Department of Biostatistics, University of Pittsburgh, PA 15261, USA
Am J Ind Med 36:114-21. 1999..All the plants were located within the United States and cohort eligibility required some work experience within the period of the late 1940s through the mid 1960s... - Vibroacoustic stimulation enhances visualization of the four-chamber cardiac view in the third trimesterN Lazebnik
Department of Obstetrics, Magee Womens Research Institute, Pittsburgh, USA
Ultrasound Obstet Gynecol 8:309-13. 1996..1 and 37.0 weeks. We conclude that in a selected group of patients vibroacoustic stimulation can be used to enhance visualization of the four-chamber view... - Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife womenDavid Cella
National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, PA, USA
Breast Cancer Res Treat 109:515-26. 2008..To evaluate scalability of a symptom scale administered to women enrolled in the Breast Cancer Prevention Trial (BCPT) (P-1) conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP)... - Application of smoothing methods to evaluate treatment-prognostic factor interactions in breast cancer dataJong-Hyeon Jeong
University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Cancer Invest 24:288-93. 2006..The progesterone level does not affect the size of benefit from tamoxifen, but the benefit from the addition of the chemotherapy is greater for patients with higher progesterone level... - Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular riskPatricia K Agatisa
Department of Obstetics and Gynecology, School of Medicine, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA
Am J Physiol Heart Circ Physiol 286:H1389-93. 2004..006). These data demonstrate that women with a history of preeclampsia exhibit impaired endothelial function up to 1 yr postpartum. This observation may explain their increased risk for hypertension and cardiovascular disease... - Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trialEleftherios P Mamounas
Aultman Health Foundation, 2600 6th St, SW Canton, OH 44710, USA
J Clin Oncol 26:1965-71. 2008.... - Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyVictor G Vogel
J Natl Cancer Inst 94:1504. 2002 - Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention TrialMary Cushman
Department of Medicine, University of Vermont, Burlington, VT, USA
Br J Haematol 120:109-16. 2003..Reductions of antithrombin and protein S, but not protein C or APC resistance, might relate to the increased risk of venous thrombosis associated with tamoxifen treatment... - Effects of tamoxifen on benign breast disease in women at high risk for breast cancerElizabeth Tan-Chiu
Cancer Research Network, 350 84th Avenue, Suite 305, Plantation, FL 33324, USA
J Natl Cancer Inst 95:302-7. 2003..We examined the effect of tamoxifen treatment on the incidence of benign breast disease and the number of breast biopsies in the same group of women... - Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1)Mary S Beattie
Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, CA, USA
J Natl Cancer Inst 98:110-5. 2006..The purpose of this study was to determine whether sex hormone levels were associated with breast cancer risk and with response to tamoxifen in a high-risk population... - Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP systemClifford A Hudis
Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:2127-32. 2007.... - Benign gynecologic conditions among participants in the Breast Cancer Prevention TrialEva Chalas
Department of Obstetrics, Gynecology and Reproductive Medicine, Stony Brook University, State University of New York, Stony Brook, NY
Am J Obstet Gynecol 192:1230-7; discussion 1237-9. 2005..This study was undertaken to report on the benign gynecologic conditions occurring among women with an intact uterus at enrollment in the Breast Cancer Prevention Trial of the National Surgical Adjuvant Breast and Bowel Project... - Projecting individualized absolute invasive breast cancer risk in African American womenMitchell H Gail
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Executive Plaza South Rm 8032, Bethesda, MD 20892 7244, USA
J Natl Cancer Inst 99:1782-92. 2007..We developed a model for projecting absolute risk of invasive breast cancer in African American women and compared its projections with those from the Breast Cancer Risk Assessment Tool... - Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trialDavid N Krag
University of Vermont, College of Medicine, Burlington, VT 05405 0068, USA
Lancet Oncol 8:881-8. 2007..The aim of this paper is to report the technical success and accuracy of SLN resection plus ALND versus SLN resection alone...